116 related articles for article (PubMed ID: 37577652)
1. The Amphiregulin/EGFR axis has limited contribution in controlling autoimmune diabetes.
Raugh A; Jing Y; Bettini ML; Bettini M
Res Sq; 2023 Aug; ():. PubMed ID: 37577652
[TBL] [Abstract][Full Text] [Related]
2. The amphiregulin/EGFR axis has limited contribution in controlling autoimmune diabetes.
Raugh A; Jing Y; Bettini ML; Bettini M
Sci Rep; 2023 Oct; 13(1):18653. PubMed ID: 37903947
[TBL] [Abstract][Full Text] [Related]
3. Thymically-derived Foxp3+ regulatory T cells are the primary regulators of type 1 diabetes in the non-obese diabetic mouse model.
Holohan DR; Van Gool F; Bluestone JA
PLoS One; 2019; 14(10):e0217728. PubMed ID: 31647813
[TBL] [Abstract][Full Text] [Related]
4. Gata3 is detrimental to regulatory T cell function in autoimmune diabetes.
Kiaf B; Bode K; Schuster C; Kissler S
bioRxiv; 2023 Mar; ():. PubMed ID: 36993342
[TBL] [Abstract][Full Text] [Related]
5. Th1-Like ICOS+ Foxp3+ Treg Cells Preferentially Express CXCR3 and Home to β-Islets during Pre-Diabetes in BDC2.5 NOD Mice.
Kornete M; Mason ES; Girouard J; Lafferty EI; Qureshi S; Piccirillo CA
PLoS One; 2015; 10(5):e0126311. PubMed ID: 25946021
[TBL] [Abstract][Full Text] [Related]
6. β-cell-specific IL-2 therapy increases islet Foxp3+Treg and suppresses type 1 diabetes in NOD mice.
Johnson MC; Garland AL; Nicolson SC; Li C; Samulski RJ; Wang B; Tisch R
Diabetes; 2013 Nov; 62(11):3775-84. PubMed ID: 23884888
[TBL] [Abstract][Full Text] [Related]
7. ICOS-dependent homeostasis and function of Foxp3+ regulatory T cells in islets of nonobese diabetic mice.
Kornete M; Sgouroudis E; Piccirillo CA
J Immunol; 2012 Feb; 188(3):1064-74. PubMed ID: 22227569
[TBL] [Abstract][Full Text] [Related]
8. Alpha-Lipoic Acid Inhibits Spontaneous Diabetes and Autoimmune Recurrence in Non-Obese Diabetic Mice by Enhancing Differentiation of Regulatory T Cells and Showed Potential for Use in Cell Therapies for the Treatment of Type 1 Diabetes.
Huang SH; Kuo SL; Chen SJ; Lin JR; Chen YW; Hong ZJ; Sytwu HK; Lin GJ
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163121
[TBL] [Abstract][Full Text] [Related]
9. Immune- and non-immune-mediated roles of regulatory T-cells during wound healing.
Zaiss DM; Minutti CM; Knipper JA
Immunology; 2019 Jul; 157(3):190-197. PubMed ID: 30866049
[TBL] [Abstract][Full Text] [Related]
10. Amphiregulin activates regulatory T lymphocytes and suppresses CD8+ T cell-mediated anti-tumor response in hepatocellular carcinoma cells.
Yuan CH; Sun XM; Zhu CL; Liu SP; Wu L; Chen H; Feng MH; Wu K; Wang FB
Oncotarget; 2015 Oct; 6(31):32138-53. PubMed ID: 26451607
[TBL] [Abstract][Full Text] [Related]
11. KLRG1 expression identifies short-lived Foxp3
Kornete M; Mason E; Istomine R; Piccirillo CA
Autoimmunity; 2017 Sep; 50(6):354-362. PubMed ID: 28850267
[TBL] [Abstract][Full Text] [Related]
12. Cyclophosphamide-induced type-1 diabetes in the NOD mouse is associated with a reduction of CD4+CD25+Foxp3+ regulatory T cells.
Brode S; Raine T; Zaccone P; Cooke A
J Immunol; 2006 Nov; 177(10):6603-12. PubMed ID: 17082572
[TBL] [Abstract][Full Text] [Related]
13. Transient Depletion of Foxp3
Watts D; Janßen M; Jaykar M; Palmucci F; Weigelt M; Petzold C; Hommel A; Sparwasser T; Bonifacio E; Kretschmer K
Front Immunol; 2021; 12():720133. PubMed ID: 34447385
[TBL] [Abstract][Full Text] [Related]
14. Foxp3
Dial CF; Tune MK; Doerschuk CM; Mock JR
Am J Respir Cell Mol Biol; 2017 Aug; 57(2):162-173. PubMed ID: 28296468
[TBL] [Abstract][Full Text] [Related]
15. The Amphiregulin/EGFR axis protects from lupus nephritis via downregulation of pathogenic CD4
Melderis S; Warkotsch MT; Dang J; Hagenstein J; Ehnold LI; Herrnstadt GR; Niehus CB; Feindt FC; Kylies D; Puelles VG; Berasain C; Avila MA; Neumann K; Tiegs G; Huber TB; Tharaux PL; Steinmetz OM
J Autoimmun; 2022 May; 129():102829. PubMed ID: 35468361
[TBL] [Abstract][Full Text] [Related]
16. Human cord blood stem cell-modulated regulatory T lymphocytes reverse the autoimmune-caused type 1 diabetes in nonobese diabetic (NOD) mice.
Zhao Y; Lin B; Darflinger R; Zhang Y; Holterman MJ; Skidgel RA
PLoS One; 2009; 4(1):e4226. PubMed ID: 19156219
[TBL] [Abstract][Full Text] [Related]
17. High Thymic Output of Effector CD4
Zhao Y; Alard P; Kosiewicz MM
J Immunol Res; 2019; 2019():8785263. PubMed ID: 31281853
[TBL] [Abstract][Full Text] [Related]
18. Key role of the GITR/GITRLigand pathway in the development of murine autoimmune diabetes: a potential therapeutic target.
You S; Poulton L; Cobbold S; Liu CP; Rosenzweig M; Ringler D; Lee WH; Segovia B; Bach JF; Waldmann H; Chatenoud L
PLoS One; 2009 Nov; 4(11):e7848. PubMed ID: 19936238
[TBL] [Abstract][Full Text] [Related]
19. Endogenous expansion of regulatory T cells leads to long-term islet graft survival in diabetic NOD mice.
Shi Q; Lees JR; Scott DW; Farber DL; Bartlett ST
Am J Transplant; 2012 May; 12(5):1124-32. PubMed ID: 22299822
[TBL] [Abstract][Full Text] [Related]
20. Combination Therapy Using IL-2/IL-2 Monoclonal Antibody Complexes, Rapamycin, and Islet Autoantigen Peptides Increases Regulatory T Cell Frequency and Protects against Spontaneous and Induced Type 1 Diabetes in Nonobese Diabetic Mice.
Manirarora JN; Wei CH
J Immunol; 2015 Dec; 195(11):5203-14. PubMed ID: 26482409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
